Shares of Evolus, Inc. (NASDAQ:EOLS) have been given a consensus recommendation of “Hold” by the nine analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.38.
Separately, SVB Leerink reissued a “buy” rating and set a $18.00 target price on shares of Evolus in a research note on Sunday, August 8th.
In other news, major shareholder Medytox Inc. acquired 44,000 shares of Evolus stock in a transaction that occurred on Wednesday, August 25th. The stock was bought at an average price of $11.12 per share, with a total value of $489,280.00. Following the completion of the purchase, the insider now owns 7,346,652 shares in the company, valued at $81,694,770.24. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Alphaeon 1 Llc sold 2,597,475 shares of Evolus stock in a transaction that occurred on Thursday, September 2nd. The shares were sold at an average price of $9.50, for a total transaction of $24,676,012.50. Following the sale, the insider now owns 6,064,871 shares of the company’s stock, valued at $57,616,274.50. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 137,000 shares of company stock valued at $1,470,460 and have sold 2,762,335 shares valued at $26,455,493. Company insiders own 7.60% of the company’s stock.
NASDAQ:EOLS traded down $0.26 on Monday, hitting $7.96. The company had a trading volume of 647,993 shares, compared to its average volume of 993,827. Evolus has a 52 week low of $2.85 and a 52 week high of $17.38. The firm has a 50 day moving average of $10.48 and a two-hundred day moving average of $11.19. The stock has a market capitalization of $434.42 million, a price-to-earnings ratio of -2.11 and a beta of 2.31.
Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.01). Evolus had a negative net margin of 171.55% and a negative return on equity of 209.46%. The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.51 million. As a group, equities analysts expect that Evolus will post -1.5 earnings per share for the current fiscal year.
Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Featured Article: What is a stock portfolio tracker?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.